A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism

European Journal of Endocrinology

Volumn 150, Issue 3, 2004, Pages 351-354

  Keleştimur, Fahrettin ^a   Everest, Hatice ^a   Ünlühizarci, Kürşad ^a   Bayram, Fahri ^a   Şahin, Yilmaz ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HIRSUTISM; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

ADULT; ALDOSTERONE ANTAGONISTS; DEHYDROEPIANDROSTERONE SULFATE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FINASTERIDE; FOLLICLE STIMULATING HORMONE; HIRSUTISM; HUMANS; LUTEINIZING HORMONE; SEX HORMONE-BINDING GLOBULIN; SPIRONOLACTONE; TESTOSTERONE;

EID: 17444441253     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500351     Document Type: Article

References (29)

1. Conn JJ & Jacobs HS. The clinical management of hirsutism. European Journal of Endocrinology 1997 136 339-348.
2. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. Journal of Clinical Endocrinology and Metabolism 1995 80 2559-2563.
3. Erenus M, Yücelten D, Durmuşoǧlu F & Gü rbüz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertility and Sterility 1997 68 1000-1003.
4. Shaw JC. Spironolactone in dermatologic therapy. Journal of the American Academy of Dermatology 1991 24 236-243.
5. McMullen GR & Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. Journal of Endocrinological Investigation 1993 16 925-932.
6. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD & Russell DW. Genetic and pharmacological evidence for more than one human steroid 5-α reductase. Journal of Clinical Investigation 1992 89 293-300.
7. Ciotta L, Cianci A, Calogero AE, Palumbo MA, Marletta E, Sciuto A et al. Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertility and Sterility 1995 64 299-306.
8. Keleştimur F & Şahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertility and Sterility 1998 69 66-69.
9. Sahin Y, Dilber S & Keleştimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertility and Sterility 2001 75 496-500.
10. Pittaway DE, Maxson WS & Wentz AC. Spironolactone in combination drug therapy for unresponsive hirsutism. Fertility and Sterility 1985 43 878-882.
11. Ünlühizarci K, Everest H, Bayram F & Keleştimur F. Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Fertility and Sterility 2002 78 1331-1333.
12. Keleştimur F, Şahin Y, Ayata D & Tutuş A. The prevalence of non-classic adrenal hyperplasia due to 11β-hydroxylase deficiency among hirsute women in a Turkish population. Clinical Endocrinology 1996 45 381-384.
13. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology and management. American Journal of Obstetrics and Gynecology 1981 140 815-830.
14. Zawadki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In Polycystic Ovary Syndrome. pp 377-384. Eds Dunaif A, Givens JR, Haselfine F & Merriam GR. Boston: Blackwell, 1992.
15. AACE Hyperandrogenism Guidelines, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocrine Practice 2001 7 121-134.
16. Bayram F, Ünlühizarci K & Keleştimur F. Potential utility of insulin sensitizers in the treatment of patients with polycystic ovary syndrome. Treatments in Endocrinology 2002 1 45-53.
17. Simard J, Luthy I, Guay J, Belanger A & Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Molecular and Cellular Endocrinology 1986 44 261-270.
18. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone P et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2000 85 89-94.
19. Müderris II, Bayram F, Şahin Y, Keleştimur F, Tutuş A & Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertility and Sterility 1996 66 220-222.
20. Müderris II, Bayram F & Güven M. A prospective, randomized trial comparing flutamide (250 mg/day) and finasteride (5 mg/day) in the treatment of hirsutism. Fertility and Sterility 2000 73 984-987.
21. Bayram F, Müderris II, Şahin Y & Keleştimur F. Finasteride treatment for one year in 35 hirsute patients. Experimental and Clinical Endocrinology and Diabetes 1999 107 195-197.
22. Crosby PDA & Rittmaster RS. Predictors of clinical response in hirsute women treated with spironolactone. Fertility and Sterility 1991 55 1076-1081.
23. Wong IL, Morris RS, Chang L, Spahn M, Stanczyk FZ & Lobo R. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. Journal of Clinical Endocrinology and Metabolism 1995 80 223-238.
24. Castello R, Tosi F, Perrone F, Negri C, Muggeo M & Moghetti P. Outcome of long term treatment with the 5α-reductase inhibitor of finasteride in idiopathic hirsutism: Clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertility and Sterility 1996 66 734-740.
25. Şahin Y, Bayram F, Keleştimur F & Müderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. Journal of Endocrinological Investigation 1998 21 348-352.
26. Bayram F, Müderris I, Güven M & Keleştimur F. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. European Journal of Endocrinology 2002 147 467-471.
27. Lobo RA, Shoupe D, Serafini P, Brinton D & Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertility and Sterility 1985 43 200-205.
28. Carmina E & Lobo RA. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstetrics and Gynecology 1991 78 845-849.
29. Schriock EA & Schriock ED. Treatment of hirsutism. Clinical Obstetrics and Gynecology 1991 34 852-863.